Abstract Purpose: Gastric cancer is heterogeneous clinically and histologically, and prognosis prediction by tumor grade or type is difficult. Although previous studies have suggested that frozen tissueb ased molecular classifications effectively predict prognosis, prognostic classification on formalin-fixed tissue is needed, especially in early gastric cancer. Experimental Design: We immunostained 659 consecutive gastric cancers using 56 tumorassociated antibodies and the tissue array method. Hierarchical cluster analyses were done before and after feature selection. To optimize classifier number and prediction accuracy for prognosis, a supervised analysis using a support vector machine algorithm was used. Results: Of 56 gene products, 27 survival-associated proteins were selected (feature selection), and hierarchical clustering identified two clusters: cluster 1and cluster 2. Cluster 1 cancers were more likely to have intestinal type, earlier stage, and better prognosis than cluster 2 (P < 0.05).
The incidence and mortality of gastric cancer have declined steadily over the past several decades. Nonetheless, gastric cancer remains a major public health issue as the fourth most common cancer and the second leading cause of cancer death worldwide (1, 2) . Gastric cancer is a heterogeneous disease both histologically and genetically, and patient outcome is difficult to predict using classic histologic and molecular classifications. Many histopathologic classifications, including histologic type and grade by WHO (3), Lauren's classification (4), Ming's classification (5) , and Goseki classification (6) have been applied for the prediction of patient survival, but their usefulness remains controversial (3, 7).
The incidence of small and early gastric cancer is high in Asia because the increased usage of upper endoscopy has led to the earlier detection of lesions (8) . However, despite curative resection of the primary tumor, some early gastric cancer patients succumb to the disease as a result of local or distant tumor recurrence. Adjuvant chemotherapy benefits some patients with early gastric cancer, but it is not necessary in all patients. Therefore, additional markers are required to identify those patients at risk of recurrence or poor prognosis. Recently, large-scale molecular techniques such as DNA microarrays have contributed to our understanding of the molecular complexity of gastric cancer and prognostic classification according to gene expression profile has been achieved using frozen tissue (9, 10) . However, in small and early gastric cancer patients, the detection and sampling of proper cancer tissue using gross examination is difficult. In addition, the cost, complexity, and interpretation of DNA microarrays are currently unsuitable for routine use in standard clinical settings. Therefore, prognostic classification on formalin-fixed paraffin-embedded tissue is required, especially in small and early gastric cancer.
Many candidate gene products for the prediction of patient survival have been reported in gastric cancer (11, 12) . Genetic alterations including those of p53, MUC1, CEA, E-cadherin, p16, and CD44 have been reported to play important roles in the development and progression of the disease (13 -18) . Although much has been learned of the genetic factors (19, 20) . Jacquemier et al. identified a set of 21 proteins using supervised analysis in breast cancer, the expressions of which were significantly correlated with metastasis-free survival (20) .
In this study, we immunostained 659 consecutive gastric cancers using 56 tumor-associated antibodies and the tissue array method. Gastric cancer was subclassified using classic hierarchical clustering before and after feature selection. To obtain the optimal number of classifiers and prediction accuracy for patient outcome, we did supervised analysis using a support vector machine (SVM) algorithm.
Materials and Methods
Specimens. A total of 659 consecutive, surgically resected cases of primary gastric cancer treated over a period of 1 year were identified in -methylguanine DNA-methyltransferase; PML, promyelocytic leukemia; PTEN, phosphatase and tensin homologue deleted on chromosome 10; SAP97, synapse-associated protein 97; TCF4, T-cell factor 4; XIAP, X-linked inhibitor of apoptosis protein. Tissue array methods. Twelve array blocks containing a total of 659 cases were prepared as described previously (Superbiochips Laboratories; refs. 19, 22) . Core tissue biopsies (2 mm in diameter) were taken from individual paraffin-embedded gastric tumors (donor blocks) and arranged in recipient paraffin blocks (tissue array blocks) using a trephine. As it has previously been proven that staining results obtained from different intratumoral areas in various tumors agree well (22 -25) , a core was sampled in each case. An adequate case was defined as a tumor occupying >10% of the core area. Each block contained three internal controls consisting of nonneoplastic gastric mucosa from the body, antrum, and intestinal metaplasia. Fourmicrometer-thick sections were cut from each tissue array block, deparaffinized and dehydrated.
Immunohistochemistry. Immunohistochemical staining against tumor-associated gene products was done using a streptavidin peroxidase procedure following an antigen retrieval process using microwaves or autoclaves. Commercially available antibodies were tested using a human control slide and a stomach cancer control slide for immunohistochemistry (Superbiochips Laboratories). After the test procedure, 56 antibodies, which were properly stained in each positive and negative control, were selected for this study. Table 1 and Fig. 1 list the antibodies used. The expression status of nonneoplastic gastric glands and altered expression patterns in gastric cancer are described in Table 1 . For statistical analysis of collected data, immunostaining results were considered positive when z10% of neoplastic cells were stained (19, 22) . Immunoreactivity was assessed microscopically by two independent pathologists unaware of the clinical details of individual patients. The case-by-case final consensus result was discussed and determined in a common session.
Cluster analyses. Expression data were recorded as follows: -1 was designated negative staining, 1 was designated positive staining, missing data were left blank in the data table. In this study, hierarchical cluster analyses were done using the Cluster program (complete linkage clustering) and results were displayed using TreeView (26) . All cases with missing values in >20% of the columns were excluded from the cluster analyses. We could perform an unsupervised analysis on 56 gene expressions in 601 gastric cancer samples (91.2%) of 659 consecutive samples. Of these 56 genes, 27 genes which showed significant correlations with patient outcome using the Kaplan-Meier survival method were selected (feature selection). After feature selection, we did a cluster analysis using these 27 gene expression profiles in 614 samples (93.2%) of 659 consecutive samples.
Supervised analysis using SVM and genetic algorithm. SVM and genetic algorithm were used to identify protein classifier sets associated with survival status (27) . SVM is well known for its competency among off-the-shelf classification algorithms and its performance comes from mapping of the original feature space (data space) to the higher dimensional space. The hyperplane obtained in the higher dimensional space generally shows excellent classification performance. In addition to the classification power of the SVM algorithm, selection of the input variables was important to the performance of the classification algorithm. However, it is too computationally intensive to regard all the possible combinations of 56 genes. Therefore, the genetic algorithm was applied to select an optimal subset of tumor-associated genes that yielded the best result for classification of the patient's survival status. The genetic algorithm finds an optimal solution by simulating the natural genetic selection procedure. At each step of the gene selection, prediction accuracy with 10-fold cross-validation was calculated. Crossvalidation is a widely used method for assessing the performance of a classification algorithm. It separates the whole data set into a training and test data set. For example, a 10-fold cross-validation assigns 9/10 of the whole data into the training set, and 1/10 of the whole data into the test set. When the training and test sets are assigned, the classification model is extracted from the training set and the performance of the model is examined in the test set. This process is repeated until all instances of the data set are assigned to the test set at once. By combining the SVM and genetic algorithm, the classifier consisting of a subset of 56 tumor-associated genes yielding the best classification performance with a 10-fold cross-validation was extracted. All computations were done using the R program package (e1071 package for SVM and genalg package for genetic algorithm; ref. 28 ). Statistical analyses. Either the m 2 test or Fisher's exact test (twosided) was done to determine the correlation between gene expression status and clinicopathologic variables. Survival curves were estimated using the Kaplan-Meier product-limit method, and the significance of the differences between survival curves were determined using a logrank test. Multivariate survival analyses were done using the Cox proportional hazards model. The association between clustering and regional lymph node metastasis was evaluated by multivariate logistic regression. Results were considered to be statistically significant for P < 0.05. All statistical analyses were conducted using SPSS 12.0 statistical software program (SPSS).
Results
Expression profiling of 56 proteins and hierarchical cluster analysis. The staining results of the 56 antibodies are summarized in Table 2 . By Kaplan-Meier analyses, the expression status of 27 proteins were found to be significantly associated with patient survival (P < 0.05). The overall expression patterns for 601 samples of gastric cancer were analyzed by hierarchical clustering after excluding those with values missing in >20% of the columns. The combined protein expression patterns defined two clusters: cluster A (24 cases) and cluster B (577 cases). Cluster B was subdivided into three clusters, cluster B1 (57 cases), cluster B21 (140 cases), and cluster B22 (380 cases; Fig. 2A and B) . Cluster B22 cases tended to have better survival than clusters A, B1, or B21 (P < 0.0001; Fig. 2C ). Multivariate analysis, including pTNM stage (II-IV versus I) and the molecular classification (cluster B22 versus clusters A + B21 + B1), showed that the molecular classification was an independent prognostic indicator of survival (hazard ratio, 0.654; 95% confidence interval, 0.498-0.858; P = 0.002).
Hierarchical cluster analysis of gastric cancer after feature selection. Twenty-seven survival-associated proteins were selected after univariate survival analyses of the 56-protein expression. A total of 614 gastric cancer cases were analyzed by hierarchical clustering analysis after excluding those with values missing in >20% of the columns. Tumors were separated into two main branches (Fig. 3A) . The right branch, i.e., cluster 1, consisted of 356 cases and was characterized by intestinal type (according to Lauren's classification; P = 0.002), lower lymph node metastasis (P < 0.001), and left pTNM stage (P < 0.001) compared with the lower branch, i.e., cluster 2, which consisted of 256 cases (Table 3) . Of the 614 gastric cancers, 187 cancers were limited to the mucosal or submucosal levels (pT1). In the 187 early gastric cancers, cluster 2 cancers were more likely to have metastatic lymph nodes (P = 0.026). By multivariate logistic regression analysis, cluster 2 was significantly correlated with lymph node metastasis independently of lymphatic invasion and depth of invasion (P = 0.027; Table 4 ).
Using a protein dendrogram, 27 survival-associated proteins were classified into three groups (Fig. 3B) . Group 1 consisted of proteins overexpressed in gastric cancer, e.g., CD24, hexokinase II, smad7, MUC1, S100A4, and CEA, whereas group 3 consisted of suppressor proteins, e.g., APC, smad4, KAI-1, MGMT, PML, PTEN, and E-cadherin.
To determine whether these two clusters might represent clinically distinct subgroups of patients, univariate survival analysis was done. Cluster 2 was associated with poorer prognosis compared with cluster 1 (P < 0.0001; Fig. 3C) , and multivariate analysis, including pTNM stage and the above cluster-based molecular classification, showed that the classification was an independent prognostic indicator of survival (P = 0.013; Table 5 ). Kaplan-Meier survival curves stratified by pTNM stage (stages I-IV) revealed that cluster 2 was associated with a probability of lower survival for patients with stage I or II cancer (P = 0.0005 and 0.0020, respectively; Fig. 3D and E) .
Supervised analysis using the SVM algorithm. After 1,000 iterations, the genetic algorithm selected nine protein classifiers (CEA, c-fos, caspase-1, c-kit, cytokeratin6, cytokeratin19, S100A4, HDAC1, and DNA-PKcs) which showed the best classification performance compared with other combinations of tumor-associated genes in the whole data set. The prediction accuracy of these classifiers for patient survival was 73.1% (sensitivity, 36.7%; specificity, 94.7%). When 421 samples of stage I and II tumors were analyzed, the prediction accuracy was 88.1% for nine classifiers (MUC2, MUC6, smad4, PTEN, MGMT, TCF4, rad9, cytokeratin8, and S100A6). The sensitivity of these classifiers in stage I and II tumors decreased (30%), whereas the specificity increased (99.3%). The molecular classifiers for the data set of stage III and IV tumors (n = 220) were p53, p16, KAI1, TCF4, IRS-1, cytokeratin6, GST-p, and osteonectin. The prediction accuracy for patient survival was reduced to 76% compared with that of the classifiers in stage I and II tumors. Sensitivity and specificity for prediction of patient survival showed different features. Sensitivity increased sharply (95.5%) and specificity decreased (33.8%). Results are listed in Table 6 .
Discussion
Gastric cancer is a heterogeneous disease histologically and genetically. Histologically, it is subdivided into intestinal and diffuse types by Lauren classification (4), but some gastric cancers cannot be easily classified in this way because these two types are frequently admixed within single tumors. Moreover, it is controversial as to whether Lauren's classification is an independent prognostic factor. Genetically, many earlier studies have reported genetic alterations during gastric carcinogenesis and progression, e.g., p53 mutations (29), microsatellite instability (30) , EBV infection (31), CpG island methylation (32) , and chromosomal instability (33) . Thus, gastric cancer is associated with various genetic alterations and no single genetic marker can predict gastric cancer biology or prognosis. The potential use of combinations of biomarkers instead of a single marker or histologic feature has been previously commented upon (19, 22, 34) . Moreover, high-throughput analysis based on formalin-fixed tissues is possible using the tissue array method. Recent studies have applied tissue array methods to the molecular classifications of various cancers such as breast and brain tumors (20, 35) , and protein expression profiling has been found to be clinically useful for the prognostic classification of neoplasms. The present study shows that a molecular classification of gastric cancer can be accomplished based on hierarchical cluster analysis of the immunohistochemical profiles of tumorassociated biomarkers using tissue array sections. The tissue array method enabled us to immunostain 659 formalin-fixed gastric cancer specimens with 56 tumor-associated antibodies. Moreover, using the large amount of data generated, various hierarchical cluster analyses could be done. The overall protein expression patterns defined four survivalassociated clusters, i.e., cluster A (24 cases), cluster B1 (57 cases), cluster B21 (140 cases), and cluster B22 (380 cases). Patients with cluster B22 cancers had the best prognosis among the four clusters (P < 0.0001). However, 56 markers are too many for practical use. To more accurately predict patient survival, and to reduce the number of markers, we did a feature selection using Kaplan-Meier survival analyses. Twenty-seven survival-associated proteins were selected as described in Materials and Methods. Tumors were separated into two main branches by hierarchical clustering, i.e., cluster 1 (356 cases) and cluster 2 (256 cases), and these two clusters were found to have distinct clinicopathologic features and patient outcomes.
Recently, the incidence, and thus the importance, of small and early gastric cancers have increased because of the increased use of upper gastrointestinal endoscopy (8) . Minimal resection and surgery such as endoscopic mucosal resection and laparoscopic surgery have been increasingly used to treat early gastric cancer (36) . Moreover, the prediction of lymph node metastasis in endoscopic mucosal resection specimens is clinically important and the prediction of patient survival in early gastric cancer specimens would allow accurate decisionmaking concerning postoperative management. In the present study, Kaplan-Meier survival curves that were stratified according to pTNM revealed that cluster 2 was significantly associated with poor survival for stage I and II cancers (P = 0.0005 and 0.0020, respectively). Our study contained 187 cancers that were limited to the mucosa or submucosa (pT1). Cluster 2 cancers were also more associated with the presence of metastatic lymph nodes in 187 early gastric cancers (pT1; P = 0.026), independently of lymphatic invasion (P = 0.035), indicating that the molecular classification may be applied to the prediction of lymph node metastasis or prognosis in early gastric cancer.
Using the protein dendrogram, 27 survival-associated proteins were classified into three groups. Whereas group 1 consisted of proteins overexpressed in gastric cancer, group 3 consisted of proteins lost in gastric cancer. In a previous study of breast cancer (20) , a protein dendrogram revealed four major protein clusters, i.e., estrogen receptor -associated proteins, a differentiation cluster, a mitosis cluster, and a proliferation cluster. However, in the present study, the protein groups were not well defined, which is probably due to the more heterogeneous nature of gastric cancer.
In this study, the classifications based on the 27 selected proteins were significantly associated with clinicopathologic features and prognosis. However, 27 proteins are too many for routine use. To obtain an optimal number of protein classifiers for the accurate prediction of patient outcome, 1,000 iterations were done using the genetic algorithm, and as a result, nine classifiers were chosen in the whole data set with a prediction accuracy for patient outcome of 73.1%, sensitivity of 36.7%, and specificity of 94.7%. When 421 stage I and II samples were analyzed, another nine classifiers were chosen and prediction accuracy was 88.1%, sensitivity was 30%, and specificity was 99.3%. The identified classifiers for the stage III and IV samples (n = 220) were p53, p16, KAI1, TCF4, IRS-1, cytokeratin6, GST-p, and osteonectin, and these had a prediction accuracy of 76%, sensitivity of 95.5%, and a specificity of 33.8%. These classifier numbers were found to be optimal for practical use in pathology laboratories. There was a large gap between the sensitivity and specificity of the classification analysis. This result was due to our analysis scheme. In this analysis, we used the genetic algorithm to select an optimal subset of tumorassociated genes that yielded the highest prediction accuracy with a 10-fold cross-validation. During selection, only the prediction accuracy was considered. The selected classifier genes therefore generated the optimal prediction accuracy with the sacrifice of sensitivity or specificity. Even if the sensitivity was low, the classifier genes from stage I and II data could be applied as indicators for good prognosis because the specificity is high. In cases with classifiers from stage III and IV, they could be used as the screening test for unfavorable outcome because the sensitivity is high. Further validation is needed concerning the use of the above classifiers for routine pathologic diagnoses.
In summary, we immunostained 659 consecutive gastric cancers with 56 tumor-associated antibodies using the tissue array method. With 27 survival-associated gene products, the hierarchical cluster analysis identified two clusters with different clinicopathologic features and prognoses. Moreover, the molecular classification predicted lymph node metastasis and prognosis in early stage gastric cancer. To optimize classifier numbers and accurately predict patient outcome, we did the supervised analysis using the SVM algorithm. The genetic algorithm selected nine classifiers in the whole data set, another nine classifiers in stages I and II, and eight classifiers in stages III and IV. Prediction accuracies for the patient outcomes of these classifiers were 73.1%, 88.1%, and 76%, respectively. 
